Literature DB >> 10223962

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.

P L Ho1, T L Que, D N Tsang, T K Ng, K H Chow, W H Seto.   

Abstract

The MICs of 17 antimicrobial agents for 181 Streptococcus pneumoniae strains were determined by the E-test. Overall, 69.1% were penicillin resistant (MIC > 0.06 microgram/ml). Resistance to ciprofloxacin (MIC > 2 microgram/ml), levofloxacin (MIC > 2 microgram/ml), or trovafloxacin (MIC > 1 microgram/ml) was found in 12.1, 5.5, or 2.2% of the strains, respectively. These high rates of resistance raise concerns for the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223962      PMCID: PMC89269     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae.

Authors:  K P Klugman; T D Gootz
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.

Authors:  B A Cunha; S M Qadri; Y Ueno; E A Walters; P Domenico
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

3.  Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong.

Authors:  P Ho; K Yuen; W Yam; S Sai-yin Wong; W Luk
Journal:  J Hosp Infect       Date:  1995-12       Impact factor: 3.926

4.  Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.

Authors:  E L Fasola; S Bajaksouzian; P C Appelbaum; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.

Authors:  S Hunt Gerardo; D M Citron; M C Claros; E J Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

Authors:  C Thornsberry; P Ogilvie; J Kahn; Y Mauriz
Journal:  Diagn Microbiol Infect Dis       Date:  1997-12       Impact factor: 2.803

7.  Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group.

Authors:  J F Plouffe
Journal:  Diagn Microbiol Infect Dis       Date:  1996-05       Impact factor: 2.803

8.  Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

Authors:  R Muñoz; T J Coffey; M Daniels; C G Dowson; G Laible; J Casal; R Hakenbeck; M Jacobs; J M Musser; B G Spratt
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

9.  Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan.

Authors:  C C Chiou; Y C Liu; T S Huang; W K Hwang; J H Wang; H H Lin; M Y Yen; K S Hsieh
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong.

Authors:  K M Kam; K Y Luey; S M Fung; P P Yiu; T J Harden; M M Cheung
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

  10 in total
  66 in total

1.  Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice.

Authors:  E Azoulay-Dupuis; V Rieux; M Muffat-Joly; J P Bédos; E Vallée; C Rivier; R Isturiz; C Carbon; P Moine
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones: A Growing Concern.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

Review 3.  Impact of antimicrobial agents and chemotherapy from 1972 to 1998.

Authors:  M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

4.  Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  D J Bast; J C de Azavedo; T Y Tam; L Kilburn; C Duncan; L A Mandell; R J Davidson; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Levofloxacin-resistant Streptococcus pneumoniae: second look.

Authors:  C Thornsberry; J A Karlowsky; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones.

Authors:  L Alou; M Ramirez; C García-Rey; J Prieto; H de Lencastre
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.

Authors:  Glenn A Pankuch; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

8.  Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Authors:  Glenn A Pankuch; Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

9.  Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.

Authors:  D C Richardson; D Bast; A McGeer; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

10.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.